Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (22)

« Back to Publications

Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment

Lavoie G. et al, (2025), Thorax, 80, 113 - 116

Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment.

Lavoie G. et al, (2025), Thorax, 80, 113 - 116

Species‐level, metagenomic and proteomic analysis of microbe‐immune interactions in severe asthma

Jabeen MF. et al, (2024), Allergy, 79, 2966 - 2980

Recovery of Breakthrough Asthma Attacks Treated With Oral Steroids While on Monoclonal Antibody Therapy: Protocol for a Prospective Observational Study (BOOST)

Howell I. et al, (2023), JMIR Research Protocols, 12, e46741 - e46741

Recovery of Breakthrough Asthma Attacks Treated With Oral Steroids While on Monoclonal Antibody Therapy: Protocol for a Prospective Observational Study (BOOST) (Preprint)

Howell I. et al, (2023)

MAIT cells and the microbiome.

Jabeen MF. and Hinks TSC., (2023), Frontiers in immunology, 14

Identifying Bacterial Airways Infection in Stable Severe Asthma Using Oxford Nanopore Sequencing Technologies

Jabeen MF. et al, (2022), Microbiology Spectrum, 10

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide

Couillard S. et al, (2022), Thorax, 77, 199 - 202

S50 A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial

Hinks TSC. et al, (2021), Developing treatments for COVID-19, A35.1 - A35

Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial

Hinks TSC. et al, (2021), The Lancet Respiratory Medicine, 9, 1130 - 1140

A proof-of-concept scale to predict asthma attacks: the OxfoRd Asthma attaCk risk ScaLE (ORACLE)

Couillard S. et al, (2021), TP10. TP010 CLINICAL AND POPULATION-LEVEL STUDIES OF ASTHMA, A1436 - A1436

A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial

Hinks TSC. et al, (2021)

A Randomised Clinical Trial of Azithromycin Versus Standard Care in Ambulatory COVID-19 – The ATOMIC2 Trial

Hinks TSC. et al, (2021), SSRN Electronic Journal

TO WHAT EXTENT DOES THE PROTOTYPE ORACLE SCALE PREDICT TREATMENT BENEFITS? PREDICTED VERSUS OBSERVED IMPACT OF ANTI-INFLAMMATORY TREATMENTS

Couillard S. et al, (2021), THORAX, 76, A175 - A176

A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial

Hinks TSC. et al, (2020), Trials, 21

Load More